二次性副甲状腺機能亢進症を伴う血液透析患者におけるSK-1403の用量調整試験

基本情報

NCT ID

NCT03226171

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

58

治験依頼者名

Sanwa Kagaku Kenkyusho Co., Ltd.

概要

This study is conducted to assess the efficacy and safety of SK-1403 in Hemodialysis Patients with Secondary Hyperparathyroidism. In the first treatment period, the efficacy of SK-1403 is assessed after 18 weeks of treatment with SK-1403 individually dose-adjusted . Safety is also assessed during this period. Patients who completed the first treatment period proceed to the second treatment period and receive the treatment with SK-1403 for 34 weeks. Efficacy and safety of SK-1403 are also assessed during this period.

対象疾患

介入

依頼者（Sponsor）